MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. IRMD
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

iRadimed (IRMD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

iRadimed
NasdaqGM•Healthcare•Medical Devices
$82.22+0.35(<0.01%)Pre-market
Market Cap
$1.06B
P/E
45.9x
P/S
12.3x
P/B
10.4x

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.

A

How this company scores

ExcellentMetricSide Score: 80/100

Strongest: Cash & Earnings Quality (23/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability22/25
Growth20/25
Balance Sheet & Red Flags15/25
Cash & Earnings Quality23/25
Strengths
Rising free cash flowStrong marginsHigh ROEInterest easily covered

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 45.9x5y range 27.7x – 69.4x
P/E 45.9x · above its 20-quarter median

Currently above its 20-quarter median.

P/S · 12.3x5y range 6.7x – 14.9x
P/S 12.3x · above its 20-quarter median

Currently above its 20-quarter median.

P/B · 10.4x5y range 4.8x – 13.2x
Price & Volume
Market Cap $1.06B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$86.34M
7Q
Q. Revenue
$20.47M
2Q
TTM EBITDA
$29.78M
19%
TTM Op. Income
$27.56M
16%
Q. Op. Income
$6.39M
6%
TTM Net Income
$23.05M
12%
Q. Net Income
$5.22M
2Q
EPS
$0.41
2Q
Shares Out.
$12.78M
7Q
$86.34M in TTM revenue grew 11.2% YoY, reaching $20.47M last quarter. TTM EBITDA of $29.78M and TTM operating income of $27.56M show growth is flowing through to the bottom line. TTM net income of $23.05M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
74.1%
5%
EBITDA Margin
33.2%
2Q
Op. Margin
31.2%
6%
Net Margin
25.5%
2Q
Op. margin of 31.2% is down 2.0% YoY — costs are rising relative to revenue. Net margin at 25.5% and gross margin of 74.1% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 6% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
45.9x
2Q
P/S Ratio
12.3x
2Q
P/B Ratio
10.4x
2Q
At 45.9x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 12.3x and P/B of 10.4x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$114.97M
2Q
Cash
$59.08M
2Q
Long-Term Debt
N/A
Book Value
$101.75M
2Q
D/E Ratio
N/A
Debt/EBITDA
0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$5.94M
23%
TTM Free Cash Flow
$25.12M
4Q
FCF Margin
29.1%
4Q
FCF / Net Income
1.1
4Q
TTM FCF of $25.12M on $5.94M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 10.4x
· above its 20-quarter median

Currently above its 20-quarter median.